Evidence map›Paper›PMID 38170170›Full record

ArticleJournal of medicinal chemistry2024

Design, Synthesis, and Evaluation of New 1

Fadi Soukarieh, Alaa Mashabi, William Richardson, Eduard Vico Oton, Manuel Romero, Jean-Frédéric Dubern, Shaun N Robertson, Simone Lucanto, Zoe Markham-Lee, Tomás Sou and 10 more

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of medicinal chemistry, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
2.6field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 11 citations in OpenAlex.

  1. Review
  2. Review
  3. Anti-QS Strategies AgainstMicroorganisms · 2025
    Review
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors at 3 institutions in 3 countries.

Fadi SoukariehSchool of Life Sciences, University of Nottingham Biodiscovery Institute, University of Nottingham, Nottingham NG7 2RD, U.K.ORCID 0000-0002-6730-2543
Alaa MashabiSchool of Pharmacy, University of Nottingham Biodiscovery Institute, University of Nottingham, Nottingham NG7 2RD, U.K.ORCID 0000-0002-4807-2869
William RichardsonSchool of Pharmacy, University of Nottingham Biodiscovery Institute, University of Nottingham, Nottingham NG7 2RD, U.K.
Eduard Vico OtonSchool of Life Sciences, University of Nottingham Biodiscovery Institute, University of Nottingham, Nottingham NG7 2RD, U.K.
Manuel RomeroSchool of Life Sciences, University of Nottingham Biodiscovery Institute, University of Nottingham, Nottingham NG7 2RD, U.K.
Jean-Frédéric DubernSchool of Life Sciences, University of Nottingham Biodiscovery Institute, University of Nottingham, Nottingham NG7 2RD, U.K.
Shaun N RobertsonSchool of Life Sciences, University of Nottingham Biodiscovery Institute, University of Nottingham, Nottingham NG7 2RD, U.K.
Simone LucantoSchool of Life Sciences, University of Nottingham Biodiscovery Institute, University of Nottingham, Nottingham NG7 2RD, U.K.
Zoe Markham-LeeSchool of Pharmacy, University of Nottingham Biodiscovery Institute, University of Nottingham, Nottingham NG7 2RD, U.K.
Tomás SouDepartment of Pharmacy, Uppsala University, Uppsala SE-751 23, Sweden.ORCID 0000-0002-7570-5545
Irena Kukavica-IbruljInstitut de Biologie Intégrative et des SystèmesUniversité Laval, Quebec G1V 0A6, Canada.
Roger C LevesqueInstitut de Biologie Intégrative et des SystèmesUniversité Laval, Quebec G1V 0A6, Canada.
Christel A S BergstromDepartment of Pharmacy, Uppsala University, Uppsala SE-751 23, Sweden.ORCID 0000-0002-8917-2612
Nigel HallidaySchool of Life Sciences, University of Nottingham Biodiscovery Institute, University of Nottingham, Nottingham NG7 2RD, U.K.
Barrie KellamSchool of Pharmacy, University of Nottingham Biodiscovery Institute, University of Nottingham, Nottingham NG7 2RD, U.K.ORCID 0000-0003-0030-9908
Jonas EmsleySchool of Pharmacy, University of Nottingham Biodiscovery Institute, University of Nottingham, Nottingham NG7 2RD, U.K.
Stephan HeebSchool of Life Sciences, University of Nottingham Biodiscovery Institute, University of Nottingham, Nottingham NG7 2RD, U.K.ORCID 0000-0002-5079-3622
Paul WilliamsSchool of Life Sciences, University of Nottingham Biodiscovery Institute, University of Nottingham, Nottingham NG7 2RD, U.K.
Michael J StocksSchool of Pharmacy, University of Nottingham Biodiscovery Institute, University of Nottingham, Nottingham NG7 2RD, U.K.ORCID 0000-0003-3046-137X
Miguel CámaraSchool of Life Sciences, University of Nottingham Biodiscovery Institute, University of Nottingham, Nottingham NG7 2RD, U.K.
University of Nottingham · GBUniversité Laval · CAUppsala University · SE

Funding

Wellcome Trust
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Pseudomonas InfectionsQuinolonesAnti-Bacterial AgentsBacterial ProteinsBiofilmsHumansImidazolesPseudomonas aeruginosaQuorum SensingVirulence FactorsAnti-Bacterial AgentsBacterial ProteinsImidazolesQuinolonesVirulence Factors

Identifiers

PMID38170170
PMCPMC10823468
OpenAlexW4390546062

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.